Please sign in to follow a disease.
Aspergillosis
MONDO:0005657Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.
57 clinical trials for this condition and its sub-types, 20 tagged with Aspergillosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Aspergillosis
-
Pulmonary aspergilloma 11 trials · 38 incl. sub-types
2 sub-types
- Invasive aspergillosis 31 trials
- Malt worker's lung 0 trials
-
Allergic bronchopulmonary aspergillosis 15 trials
1 sub-type
- Malt worker's lung 0 trials
-
Neuroaspergillosis 1 trial
-
Aspergillus niger infection 0 trials
-
Can a booster for the immune system tame a Slow-Moving lung fungus?
Disease control OngoingThis trial tests whether adding interferon-gamma to standard antifungal medication can help people with chronic pulmonary aspergillosis, a progressive lung infection caused by the Aspergillus fungus. The study will include 50 adults starting antifungal treatment, who will be rand…
Phase 2 • Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for rare lung infection: weekly drug shows promise in early trial
Disease control OngoingThis study tests a drug called rezafungin for people with a long-term lung infection caused by a fungus (chronic pulmonary aspergillosis) who have few other treatment choices. About 60 adults will receive the drug once a week for 6 months. Researchers will check if the treatment …
Phase 2 • Sponsor: Mundipharma Research Limited • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC